Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Study Overview
=================
Brief Summary
-----------------
This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Detailed Description
-----------------
The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Official Title
-----------------
Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Conditions
-----------------
Airway Response

Intervention / Treatment
-----------------
* Drug: alfentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I and II patients Age 18 to 49 years old Minor elective day care surgery (> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids. Exclusion Criteria: Potential difficult airway Reactive airway disease or sign and symptoms of upper respiratory tract infection. History of cardiac, pulmonary and renal diseases Body Mass Index > 30 kgm2. Risk of aspiration. Poor dentition with high risk of damage. Patient refusal.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: alfentanil<br>patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods | Drug: alfentanil<br>* Alfentanil is administered intravenously at the end of surgery.<br>* Other names: Rapifen;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patient with airway complication |  | after administration of alfentanil and within 1 min of LMA removal | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alfentanil, optimal dose, laryngeal mask airway